
LeonaBio Inc (LONA) Stock Forecast & Price Target
LeonaBio Inc (LONA) Analyst Ratings
Bulls say
LeonaBio is currently enrolling the Ph. 3 ELAINE-3 trial of lasofoxifene + abema vs. fulvestrant + abema in approximately 600 post-CDK4/6 ER+/HER2- breast cancer patients with an ESR1 mutation, a treatment combination that could potentially leapfrog other novel endocrine therapies currently being evaluated as monotherapies. LeonaBio's financials are strong, with over $50 million in cash as of 2Q26, and the company is well-funded to execute the ELAINE-3 trial and pursue other potential drug candidates in its pipeline. Additionally, LeonaBio's focus on developing novel therapies for high unmet medical needs, such as metastatic breast cancer and ALS, positions the company well for potential success in these areas.
Bears say
LeonaBio is currently facing major challenges as their clinical trials for their key drug candidates, lasofoxifene and ATH-1105, have not shown significant promise. Renewed interest in their drugs has not led to an increase in stock value as their most recent data did not meet primary and secondary endpoints. Additionally, a previous program for Alzheimer's failed to meet its primary endpoint, further dampening the potential outlook for the company.
This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.
LeonaBio Inc (LONA) Analyst Forecast & Price Prediction
Start investing in LeonaBio Inc (LONA)
Order type
Buy in
Order amount
Est. shares
0 shares